The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome,
but 5–10% of cases will develop metastatic disease. Around 60–70% of this subset, hence …

In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …

This ESMO Clinical Practice Guideline provides updated state-of-the-art recommendations
on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a …

Tumor progression and immune evasion result from multiple oncogenic and
immunosuppressive signals within the tumor microenvironment. The combined blockade of …

Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until
recently, there were limited therapeutic options. However, over the last decade our …

Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in
cancer therapy. Displaying activity in multiple solid tumors, it has been approved in …

Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1–
3, fibroblast growth factor receptors 1–4, RET, KIT, and platelet-derived growth factor …

Background Lenvatinib is a multi-kinase inhibitor approved for patients with radioactive
iodine (RAI)–resistant differentiated thyroid cancer (DTC). Before the drug approval from the …

Abstract Background In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of
the Thyroid (SELECT), lenvatinib significantly improved efficacy outcomes versus placebo in …

We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid
cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary …